| pubmed-article:16215717 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16215717 | lifeskim:mentions | umls-concept:C0042210 | lld:lifeskim |
| pubmed-article:16215717 | lifeskim:mentions | umls-concept:C0920425 | lld:lifeskim |
| pubmed-article:16215717 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:16215717 | pubmed:dateCreated | 2006-4-28 | lld:pubmed |
| pubmed-article:16215717 | pubmed:abstractText | A target tumor-derived whole cancer cell therapeutic vaccine was developed based on an in vitro pre-treatment by photodynamic therapy (PDT) and was investigated using a poorly immunogenic tumor model. The vaccine was produced by incubating in vitro expanded mouse squamous cell carcinoma SCCVII cells for 1 h with photosensitizer benzoporphyrin derivative (BPD), then exposing to light (690 nm, 1 J/cm2) and finally to a lethal X-ray dose. Treatment of established subcutaneous SCCVII tumors growing in syngeneic C3H/HeN mice with 2 x 10(7) PDT-vaccine cells per mouse by a peritumoral injection produced a significant therapeutic effect, including growth retardation, regression and cures. Tumor specificity of this PDT-generated vaccine was demonstrated by its ineffectiveness when prepared from a mismatched tumor cell line. Vaccine cells retrieved from the treatment site at 1 h postinjection were intermixed with dendritic cells (DC), exhibited heat shock protein 70 on their surface, and were opsonized by complement C3. Tumor-draining lymph nodes treated by the PDT-vaccine contained dramatically increased numbers of DC as well as B and T lymphocytes (with enlarged memory phenotype fraction in the latter), while high levels of surface-bound C3 were detectable on DC and to a lesser extent on B cells. The PDT-vaccine produced no therapeutic benefit against tumors growing in C3-deficient hosts. It is suggested that surface expression of heat shock proteins and complement opsonization are the two unique features of PDT-treated cells securing avid immune recognition of vaccinated tumor and the development of a strong and effective antitumor adaptive immune response. | lld:pubmed |
| pubmed-article:16215717 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16215717 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16215717 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16215717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16215717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16215717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16215717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16215717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16215717 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16215717 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16215717 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16215717 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:16215717 | pubmed:author | pubmed-author:KorbelikMlade... | lld:pubmed |
| pubmed-article:16215717 | pubmed:author | pubmed-author:SunJinghaiJ | lld:pubmed |
| pubmed-article:16215717 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16215717 | pubmed:volume | 55 | lld:pubmed |
| pubmed-article:16215717 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16215717 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16215717 | pubmed:pagination | 900-9 | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:meshHeading | pubmed-meshheading:16215717... | lld:pubmed |
| pubmed-article:16215717 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16215717 | pubmed:articleTitle | Photodynamic therapy-generated vaccine for cancer therapy. | lld:pubmed |
| pubmed-article:16215717 | pubmed:affiliation | British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, V5Z 1L3, BC, Canada. mkorbelik@bccrc.ca | lld:pubmed |
| pubmed-article:16215717 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16215717 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:16215717 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16215717 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16215717 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16215717 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16215717 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16215717 | lld:pubmed |
